期刊文献+

托伐普坦对老年慢性心力衰竭患者的疗效及对心容量负荷、血清炎症因子的影响 被引量:17

Clinical effectiveness of torvalptan for chronic heart failure in elderly patients and its effect on cardiac capacity load and serum inflammatory factors
下载PDF
导出
摘要 目的:观察托伐普坦治疗老年慢性心力衰竭(CHF)患者的临床疗效及对心容量负荷、血清炎症因子的影响。方法:将130例老年CHF患者分为对照组与观察组,对照组给予常规治疗,观察组在对照组的基础上给予托伐普坦治疗。观察2组患者治疗前及治疗3个月后心容量负荷指标、血清炎性因子表达水平、心功能指标及血清钠水平的变化情况,并评估其临床疗效。结果:2组临床疗效比较,差异有统计学意义(P<0.05);治疗后,2组患者心容量负荷指标、血清炎症因子与心功能指标均较治疗前改善(均P<0.05),且观察组各项指标均优于对照组(均P<0.05);治疗后,观察组患者血清钠水平较治疗前升高(P<0.05),对照组较治疗前降低(P<0.05),观察组患者血清钠水平高于对照组(P<0.05)。结论:托伐普坦可提高老年CHF患者的临床疗效,降低患者心容量负荷,预防低钠血症,抑制血清炎症因子过高表达。 Objective:To observe the clinical effectiveness of toparptan for elderly patients with chronic heart failure(CHF)and its effect on cardiac capacity load and serum inflammatory factors.Methods:130 elderly patients with CHF were divided into the control group and the observation group.The control group was given routine treatment,and the observation group was given topalptan treatment on the basis of the control group.Before and 3 months after treatment,cardiac capacity load index,serum levels of inflammatory factors,cardiac function indexes and the change of serum sodium levels were observed in two groups,and clinical effectiveness was evaluated.Results:The clinical efficacy in the observation group was better than that in the control group(P<0.05).After treatment,the indexes of cardiac capacity load,serum inflammatory factors and cardiac function were significantly improved in both groups as compared with those before treatment(P<0.05).All the indicators in the observation group were better than those in the control group(P<0.05).After treatment,serum sodium level in the observation group was significantly higher than before treatment(P<0.05),that in the control group was significantly lower than before treatment(P<0.05),and that in the observation group was significantly higher than that in the control group(P<0.05).Conclusion:Toparptan can improve the clinical effectiveness of elderly patients with CHF,reduce the load of cardiac capacity,prevent hyponatremia,and inhibit the excessive expression of serum inflammatory factors.
作者 杜香玲 DU Xiang-ling(The Second People's Hospital,Juancheng County,Heze275600,China)
出处 《内科急危重症杂志》 2019年第6期482-485,共4页 Journal of Critical Care In Internal Medicine
基金 山东中医药科学技术局项目资助(No:Z2011-1-3-19-2)
关键词 慢性心力衰竭 临床疗效 心容量负荷 炎症因子 Chronic heart failure Clinical effect Cardiac capacity load Inflammatory cytokines
  • 相关文献

参考文献4

二级参考文献28

  • 1无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3684
  • 2SATOSHI S,AKIOMI Y,TAKAYOSHI Y,et al,Acute heart failure volume control multicenter randomized(AVCMA)trial:comparison of tolvaptan and carperitide[J].J Clini Pharmacol,2 0 1 3,5 3(1 2):1 2 7 7-1 285.
  • 3American Heart Association.ACC/AHA 2008 Guidelines for the management of adults with congenital heart disease[J].J the Am Coll of Cardiol,2008,23(52):143-263.
  • 4KLEIN L,O'CONNOR C M,LEIMBERGER J D,et al.Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure:results from the outcomes of a prospective trial of intravenous milri-none for exacerbations of chronic heart failure(OPTIME-CHF)study[J].Circulation,2005,111(19):2 454-2 460.
  • 5Iyengar S, Abraham WT. Diuretic resistance in heart failure. Curr Heart Fail Rep, 2006, 3 : 41-45.
  • 6Rusinaru D, Buiciuc O, Leborgne L, et al. Relation of serum sodium level to long-term outcome after a fist hospitalization for heart failure with preserved ejection fraction. Am J Cardiol, 2009, 103 : 405-410.
  • 7Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure an analysis from the OPTMIZE- HF registry. Eur Heart J, 2007, 28: 980-988.
  • 8Nodari S, Jao GT, Chiong JR. Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients, lnt Nephrol Renovase Dis, 2010, 3: 51-60.
  • 9Kajimoto K, Abe T. Blood urea nitrogen as a marker of the acute response to addition of tolvaptan to standard therapy in patients hospitalized for acute heart failure syndromes. Int J Cardiol, 2014, 177: 589-591.
  • 10Schrier RW. Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail, 2008, 1 : 2-5.

共引文献4779

同被引文献173

引证文献17

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部